This trial is evaluating whether ELI-002 2P will improve 5 primary outcomes and 7 secondary outcomes in patients with Minimal Residual Disease. Measurement will happen over the course of 30 days after the last ELI-002 dose.
This trial requires 18 total participants across 3 different treatment groups
This trial involves 3 different treatments. ELI-002 2P is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Residual tumor is less likely to remain inactive than to remain active. However, depending on the stage in which it is discovered, residual tumor can be cured. At the highest stage, residual tumor is cured at a rate of 66%." - Anonymous Online Contributor
"Residual tumor is a significant problem in breast cancer and colorectal cancer. Most residual tumors are benign, but the rate of malignancy in residual tumor is very high." - Anonymous Online Contributor
"Patients treated with radiotherapy have a lower relapse rate than patients treated with chemotherapy alone. The use of radiotherapy for residual tumor may be justified." - Anonymous Online Contributor
"Findings from a recent study shows that residual tumor persists very fast; 20 to 30 weeks after surgery the residual tumors have completely disappeared. In many cases only small residual residuals can be identified." - Anonymous Online Contributor
"Residual tumor is the residual of a primary tumor following a curative treatment such as surgery of a benign tumor. The primary tumor can either regress or persist after the treatment for the benign tumors." - Anonymous Online Contributor
"Residual tumor, the size of the lung cancer is the strongest independent predictor of an increase in the development of new metastases or distant metastases." - Anonymous Online Contributor
"Between 2005 and 2010, the incidence of residual tumor was decreasing. At any given time, most adult women undergoing surgery for ER+ breast cancer should expect to have residual tumor and approximately 15-20% of women will have substantial residual tumor following surgery for ER- breast cancer." - Anonymous Online Contributor
"The survival rate of residual tumor is high for primary site. There were no differences according to the site of origin, but higher tumor stage and node metastasis were associated with death by residual tumor." - Anonymous Online Contributor
"In the elderly with a residual tumor on FDG PET/CT, the time to a second evaluation of the tumor increases as the mean age increases. There is no evidence that younger patients with a residual tumor do better than older patients in having a second evaluation. Younger patients who have a (new or) residual tumor may be treated with a watch-and-wait strategy (wait for 1–2 months). However, some patients should get a second evaluation because there is increased risk of tumor progress or new residual nodule(s) that should be examined." - Anonymous Online Contributor
"Findings from a recent study found no significant changes in adverse events or serious side effects compared with placebo in people with unresectable hepatocellular carcinoma (HCC) treated with eli-002 2p as maintenance therapy following primary liver transplantation." - Anonymous Online Contributor
"Although there is strong evidence that in multiple families with an ascertained history of nonmetastatic solid tumors that a tumor is caused by a hereditary component, a significant proportion of such families lacked an accompanying history of a nonmetastatic solid cancer. Genetic counseling may be helpful to families when a solid tumor is present at time of diagnosis, and when there is an associated solid or hematologic cancer." - Anonymous Online Contributor
"Residual tumor, even in cases with very low incidence or risk factors, can arise. It is recommended to treat residual tumor even if there are no risk factors." - Anonymous Online Contributor